Commercial scale manufacturer for Saori

RNS Number : 3515V
Plant Health Care PLC
13 December 2021
 

RNS

13 December 2021

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

 Commercial-Scale Manufacturing for Saori ® Soybean Seed Treatment

 

Plant Health Care® (AIM: PHC.L ) a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update in relation to the volume manufacture of its Saori soybean seed treatment , recently launched in Brazil with Nutrien Ag Solutions.

 

Highlights

-  Signed a production and supply agreement with a leading European-based fermentation company, securing production capacity of PHC279 , the active ingredient in its Saori soybean seed treatment , to meet projected global demand.

-  Volume production cost targets have been met, ensuring an attractive gross margin for the Company and an attractive Return on Investment (ROI) for soybean farmers in Brazil.

-  Commencing pilot-scale manufacturing of other PREtec peptides within the same facility in support of new product regulatory filings and, ultimately, commercial-scale manufacturing of a portfolio of PREtec-based products.

 

Overview

Saori, which is proven to make soy plants healthier, improve resistance to disease and increases yield in an environmentally sustainable way, is the Company's first product from its PREtec platform to be commercialised and is the first PREtec peptide approved in Brazil.

 

PREtec peptides represent a novel class of technology which stimulate the plant to defend itself. Derived from natural proteins, PREtec is an environmentally friendly approach to protecting crops and is compatible with mainstream agricultural practices.

 

The Company intends to commercialise Saori and other PREtec peptides in markets worth more than $5 billion.

The launch of PHC279 in the USA will follow, once regulatory licences have been obtained, which is anticipated in the second half of 2022.

 

Chris Richards, CEO of Plant Health Care said, "We are delighted to have achieved this critical milestone in bringing our exciting new technology to market around the world.  This new agreement establishes a first-class capability to supply Saori directly to our distribution partner in Brazil.  Initial grower response to the launch of the Saori soybean seed treatment with Nutrien Ag Solutions in Brazil has been most encouraging and we are pleased to have established manufacturing arrangements to support wider adoption of PHC279 in 2022 and beyond."

 

For further information, please contact:

Plant Health Care plc                                                                                 Tel: +1 919 926 1600

Chris Richards, CEO 

 

Arden Partners plc - Nomad & Joint Broker   Tel: +44 (0) 20 7614 5900

John Llewellyn-Lloyd / Antonio Bossi

 

Cenkos Securities plc - Joint Broker   Tel: +44 (0) 20 7391 8900

Neil McDonald / Peter Lynch

 

Vox Markets - Digital investor relations Tel: +44 (0) 7866 384707

Paul Cornelius / Kat Perez 

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and s upply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile. Find out more at Vox Markets and the company website: www.planthealthcare.com

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBCBDDRDBDGBG
UK 100

Latest directors dealings